← Eichor
Study identifier: NCT06704321 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD

Condition: Non-Alcoholic Fatty Liver Disease  ·  Sponsor: Valbiotis

PhaseNA
Planned participants70
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersYes

About this study

This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content, cardiometabolic risk factors and gut microbiota among both men and women with MASLD.

This description comes directly from the study's public registry record.

Talk to the study team

Véronique Sapone, MSc  ·  +33 (0)6 75 32 66 59  ·  veronique.sapone@valbiotis.com

Always discuss trial participation with your own doctor first.

Locations (1)

Institut sur la nutrition et les aliments fonctionnels (INAF)Québec, Quebec, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06704321